Final answer:
For community-acquired pneumonia in a patient without recent antibiotic use or allergies, moxifloxacin or doxycycline can be considered appropriate treatment options that cover both typical and atypical pathogens.
Step-by-step explanation:
Treating community-acquired pneumonia in a patient without significant comorbidities and with no recent history of antimicrobial use or known drug allergies includes various antibiotics. Empiric therapy options can vary; however, a common approach would be starting treatment with a macrolide like azithromycin or a fluoroquinolone. Both are effective against a range of bacteria that commonly cause pneumonia. Specifically, since our patient's symptoms did not resolve with amoxicillin, a non-β-lactam antibiotic would be a sensible next choice to cover potential amoxicillin-resistant strains or atypical pathogens without peptidoglycan such as Mycoplasma pneumoniae. Therefore, doxycycline (Doryx®) or moxifloxacin (Avelox®) can be considered appropriate treatments.
Moxifloxacin (Avelox®) is a fluoroquinolone with a broad spectrum of activity, including coverage against the typical and atypical pathogens that cause community-acquired pneumonia. Doxycycline is a tetracycline antibiotic and also provides broad coverage and can be used as an alternative, especially with increasing resistance concerns. Considering the broad-spectrum coverage and the absence of recent antibiotic use, either doxycycline or moxifloxacin can be chosen as an appropriate treatment option. However, specific local resistance patterns should also be taken into account when selecting an antibiotic.